Author:
You Xiangyun,Huang Shan,Wang Xin’an,Yi Cheng,Gong Niandong,Yu Junfeng,Xu Chengdang,Xiang Zhendong
Abstract
Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade≥3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Hubei Province
Natural Science Foundation of Shanghai
Subject
Endocrinology, Diabetes and Metabolism
Reference24 articles.
1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study;Fitzmaurice;JAMA Oncol,2018
2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
3. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA: Cancer J Clin,2018
4. Novel insights into the management of oligometastatic prostate cancer: A comprehensive review;Battaglia;Eur Urol Oncol,2019
5. The current landscape of treatment in non-metastatic castration-resistant prostate cancer;El-Amm;Clin Med Insights Oncol,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献